Aspen Neuroscience has completed dose escalation and treated the first two patient cohorts in its ASPIRO Phase 1/2a clinical trial evaluating ANPD001, an autologous dopaminergic neuronal cell therapy for Parkinson’s disease. According to the company, the primary goal—evaluating safety and tolerability—has been achieved with no serious adverse events reported and all patients discharged within 48 hours post-treatment.
The open-label trial enrolled patients with moderate to severe Parkinson’s disease and used escalating doses of the personalized iPSC-derived neuronal precursor cells. Secondary measures include improvements in motor symptoms, “on” time, and quality-of-life metrics. Aspen claims that ANPD001 is the most advanced autologous cell therapy in the U.S. for this indication.
The therapy is developed from each patient’s own cells, avoiding immune suppression and aiming to replace dopamine-producing neurons lost in Parkinson’s. According to the company, manufacturing incorporates proprietary genomic testing and machine learning quality controls.
Aspen Neuroscience said it is now advancing to a commercial formulation and will continue enrolling additional cohorts to further assess safety, tolerability, and early signs of efficacy. The trial is registered under NCT06344026.
